When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is Abcam stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 89 to 95.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest climbs.
Looking For Winning Stocks? Try This Simple Routine
Is Abcam Stock A Buy?
Abcam stock is now considered extended and out of buy range after clearing an 18.38 buy point in a first-stage flat base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The U.K.-based biotech company posted negative growth for both the top and bottom lines last quarter.
Abcam stock holds the No. 21 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Arcturus Therapeutics and Kiniksa Pharmaceuticals are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News"
